Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer.

BACKGROUND: Multiple treatments are available for metastatic castration-resistant prostate cancer (mCRPC), including androgen receptor signaling inhibitors (ARSI) enzalutamide and abiraterone, but therapy resistance remains a major clinical obstacle. We examined the clinical utility of low-pass whol...

Descripción completa

Detalles Bibliográficos

Publicado en:	Clinical Chemistry Vol. 69; no. 4; pp. 386 - 399
Autores principales:	Nørgaard, Maibritt, Bjerre, Marianne T., Fredsøe, Jacob, Vang, Søren, Jensen, Jørgen B., De Laere, Bram, Grönberg, Henrik, Borre, Michael, Lindberg, Johan, Sørensen, Karina D.
Formato:	Journal Article
Publicado:	Oxford University Press / USA Apr2023
Acceso en línea:	Ver este registro en EBSCOhost